The most comprehensive tumour investigation
https://www.datarpgx.de/exacta/
Exacta is a comprehensive analysis of molecular-genetic characteristics of solid tumours based on the results of several clinical studies. Especially for rare solid tumours where no guidelines are available, at an advanced stage or for tumours that are difficult to treat, Exacta provides an advantage. Exacta analyses millions of data points at the molecular level to identify all relevant targets for individual therapy.
About exacta
The conventional ‘Standard of Care’ approach does not take into consideration the overall genetic architecture of a particular patient‘s tumour. Consequently, patients could suffer due to failed therapies or aggressive relapse. It is, thus, imperative that the molecular architecture of the tumour is studied comprehensively before deciding the treatment plan, which has to be personalised to individual patients and their disease.
Exacta is a comprehensive in-depth tumour gene expression analysis. It analyses 100’s of millions of data points at the molecular level to reveal all possible targets for precision drugs.
Exacta helps unravel driver mutations and pathways that are propelling a person’s cancer through multi-analyte and multi-coordinate analysis of over 20.805 genes in the cancer genome. This analysis helps identify drugs that would be most effective for a particular solid tumour. Exacta, thus enables a highly sophisticated treatment strategy beyond the conventional perspective, even for the difficult to treat or late-stage cancers.
Exacta is particularly recommended for cancer patients where:
- first-line therapy has failed
- cancer has relapsed
- cancer is high-grade / metastatic
- challenging cancers such as stomach, oesophagus, pancreas, gall bladder, GIST etc. that have been newly diagnosed
- risk of therapy failure is high
Methodology
- Targeted Genes: SNVs, CNVs, gene amplifications, mutational burden, germline mutations
- Immunocytochemical markers: mTOR, VEGFR1, VEGFR2, EGFR, VEGFA
- RNA Sequencing: KEGG pathways (disease-related, therapy-relevant and resistance patterns)
- Pharmacogenetics: Genotyping for CYP450, transporter proteins or assessment of drug toxicity and efficacy
- Chemosensitivity: Patented in vitro cell based assay on living cells
- Liquid Biopsy: Mutation load, tumour heterogeneity
Certifications/accreditations of Datar Cancer Genetics
